Анализ гена фибриллина-1 у больных синдромом Марфана
Диссертация
Синдром Марфана (СМ) — тяжелое наследственное системное заболевание соединительной ткани, с выраженными патологическими нарушениями в скелетной, глазной и сердечно-сосудистой системах, наследуемое по аутосомно-доминантному типу (MIM 154 700). Частота встречаемости СМ в различных странах мира составляет 1:5000 — 1:10 000. Для CM характерными особенностями являются высокий процент спорадических… Читать ещё >
Содержание
- Цель и задачи исследования
- Научная новизна
- Практическая значимость
- Положения, выносимые на защиту
- Глава I. ОБЗОР ЛИТЕРАТУРЫ
- 1. 1. Эпидемиология синдрома Марфана. .И
- 1. 2. Клинические особенности синдрома Марфана. ф
- 1. 3. Молекулярно-генетическая основа синдрома Марфана
- 1. 3. 1. Структура и функция белка фибриллина
- 1. 3. 2. Структура и функция микрофибрилл
- 1. 4. Патогенез синдрома Марфана
- 1. 5. Роль других генов в клинической картине заболевания
- 1. 6. Молекулярно-генетическая диагностика синдрома Марфана
- Глава II. МАТЕРИАЛ И МЕТОДЫ
- 11. 1. Материал исследования
- 11. 2. Методы исследования
- 11. 2. 1. Выделение геномной ДНК
- 11. 2. 2. Полимеразная цепная реакция синтеза ДНК
- 11. 2. 2. 1. Исследование гена фибриллина
- 11. 2. 2. 2. Исследование гена метилентетрагидрофолатедуктазы
- 11. 2. 2. 3. Анализ полиморфных ДНК локусов
- 11. 2. 3. Рестрикционный анализ
- 11. 2. 4. SSCP-анализ
- II. 2.4.1. SSCP с щелочной денатурацией
- 11. 2. 5. Определение нуклеотидной последовательности
- 11. 3. Статистическая обработка результатов
- 111. 2. Поиск мутаций и полиморфизмов в гене фибриллина-1 у больных синдромом Марфана
- 111. 3. Анализ полиморфных ДНК-локусов MTS-1, MTS-2, MTS-4 гена фибриллина-1 у больных синдромом Марфана и в контрольной группе
- 111. 3. 1. Анализ полиморфных ДНК-локусов MTS-1, MTS-2, MTS-4 гена фибриллина-1 в контрольной группе
- 111. 3. 1. 1. Исследование полиморфного локуса MTS
- 111. 3. 1. 2. Исследование полиморфного локуса МГЗ^
- 111. 3. 1. 3. Исследование полиморфного локуса MTS
- 111. 3. 2. Анализ полиморфных ДНК-локусов MTS-J, MTS-2, MTS-4 гена фибриллина-1 у больных синдромом Марфана
- 111. 3. 3. Анализ гаплотипов полиморфных локусов MTS-1, MTS-2, MTS-4 гена фибриллина-1 в контрольной группе
- 111. 3. 1. Анализ полиморфных ДНК-локусов MTS-1, MTS-2, MTS-4 гена фибриллина-1 в контрольной группе
- 111. 4. Анализ полиморфных ДНК-локусов MTS-1, MTS-2, MTS-4 гена фибриллина-1 в семьях больных синдромом Марфана
- 111. 5. Анализ гаплотипов полиморфных локусов на нормальных и мутантных хромосомах у больных синдромом Марфана
- 111. 6. Практическое применение анализа гаплотипов в семьях с синдромом Марфана
- 111. 7. Исследование полиморфизма 677С>Т гена метилентетрагидро-фолатредуктазы {MTHFR) у больных синдромом Марфана
Список литературы
- Борисова Н. В. Исследование структуры и метаболизма коллагена при наследственных и врожденных заболеваниях соединительной ткани: Дисс. канд. мед. наук. -М., 1991.
- Гланц С. Медико-биологическая статистика. -М.: Практика, 1999. С. 130.
- Животовский Л.А. Популяционная биометрия. М.: Наука, 1991. — 272 с.
- Кадурина Т. И. Наследственные коллагенопатии. — СПб.: Невский диалект, 2000. 270 с.
- Козлова С. И., Семанова Е., Демикова Н. С., Блинникова О. Е., Наследственные синдромы и медико-генетическое консультирование. — М., 1996.-416 с.
- Котовская Е.С., Мазаев В. П., Жданова С. М., и др. Сердечно-сосудистые заболевания и дисфункция соединительной ткани. Деп.-ЦМБ.- М., 1993.-С.1−8.
- Семячкина А. Н. Диспансеризация детей с наследственными болезнями соединительной ткани. Лечение и диспансеризация детей с наследственной и врожденной патологией. — М. — 1988. С. 23−31.
- Семячкина А. Н. Клинический полиморфизм наследственных болезней соединительной ткани у детей. // Автореф. дис. докт. мед. наук. М., 1995.
- Ю.Яковлев В. М., Нечаева Г. И., Викторова И. А., Глотов А. В. // Врожденные дисплазии соединительной ткани: Тез.симп. Омск. — 1990. — С.3−5.
- П.Яковлев В. М., Нечаева Г. И., Кардио-респираторные синдромы при дисплазии соединительной ткани. Омск. — 1994. — С.217.
- Abrams W., Ma R-I., Kucich U. et al. Molecular cloning of the microfibrillar protein MFAP3 and assignment of the gene to human chromosome 5q32-q33.2 // Genomics. 1995.- Vol. 26. — P. 47−54.
- Answorth J., Murphy G., Rock M. et al. Fibrillin degradation by matrixw>metalloproteinases: implications for connective tissue remodeling // J. Biol. Chem.-1999.-Vol.240.-P. 171−181.
- Arc View GIS, Version 3.0. Environmental Systems Research Institute, Inc http://www.esri.com
- Baldock C, Koster A, Ziese U et al. The supramolecular organization of fibrillin-rich microfibrils // J. Cell Biol. 2001. — Vol.152- P.1045−1052.
- Bayers P.H. Determination of the molecular basis of Marfan syndrome: a growth industry // J.Clin. Invest.- 2004. Vol.114 — № 2 — P. 161−163.
- Beighton P., De Paepe A., Danks D. International nosology of heritableMdisorders of connective tissues. // Am. J. Med. Genet. 1986. — Vol.29. — P. 581 594.
- Biery N.J., Eldadah Z.A.,. Moore C.S., Stetten G., Spenser F., Dietz H.C. Revised genomic organization of FBN1 and significance for regulated gene expression // Genomics. Vol.56. — P.70−77.
- Black C., Withers A., Gray J. et al Correlation of a recurrent FBN1 mutation (R122C) with an atypical familial Marfan syndrome phenotype. // Hum. Mutat. -1998. suppl: S. 198−200.
- Boileau C., Jondeau G., Mizuguchi Т., Matsumoto N. Molecular genetics of У* Marfan syndrome // Current Opinion in Cardiology. 2005. — Vol.20. — P. 194 200.
- Booms P., Cisler J., Mathews K. R et al. Novel exon skipping mutation in fibrillin-1 gene: two 'hot spots' for the neonatal Marfan syndrome // Clin. Genet. -1999.-Vol.55.-P. 110−117.
- Booms P., Tiecke F., Rosenberg Т., Hagemeier C., Robinson P. Differential effect of FBN1 mutations on in vitro proteolysis of recombinant fibrillin-1 fragments. // Hum. Genet. 2000. — Vol.107. — P. 216−224.
- Brand-Saberi, В., Ebensperger, C., Wilting, J., Balling, R., Christ, B. The ventralizing effect of the notochord on somite differentiation in chick embryos //
- Anat. Embryol. 1993. -V.188. — P. 239−245.
- Bressan G. M., Daga-Gordini D., Colombatti A. et al. Emelin, a component of elastic fibers preferentially located at the elastin-microfibrillis interface // J. Cell Biol. 1993. — Vol.121 — P. 201−12.
- Buntinx I., Willems P., Spitaels S., VanReempst P., DePaepe A., Dumun J.: Neonatal Marfan syndrome with congenital arachnodactyly, flexion contractures, and severe cardiac valve insufficiency. // Med. Genet. 1991. -Vol.28. — P. 267−273.
- Cardy C.M., Hanford P.A. Metal ion dependency of microfibrillis supports a rod-like conformation for fibrillin-1 calcium binding epidermal growth factorlike domains // J. Mol. Biol. 276. — P.855−860.
- Cattaneo M. Hyperhomocysteinemia, atherosclerosis and trombosis // Tromb Haemost. 1999. — Vol.81-P. 165−76.
- Choy H-T., Shi Y-R., Hsu Y., Tsai F-J. Association between fibrillin-1 gene exon 15 and 27 polymorphisms and risk of mitral valva prolapse // J. Heart. Valve Dis. 2003. — Vol.12 — P. 475 — 481.
- Comeglio P., Evans A.L., Brice G., Cooling R.J., Child A.H. Identification of FBN1 gene mutations in patients with ectopia lentis and marfanoid habitus // Br. J. Ophthalmol. 2002. — V.86. — P. 1359−62.
- Collod-Beroud G, Le Bourdeles S, Dehaupas I et al. New update of the FBN1 mutation database 7/ Am. J. Hum. Genet. 2001 — Vol.64 (suppl) — Abstract 2583.
- Collod-Beroud G., Beroud C., Ades L. et al. Marfan database (second edition): software and database for the analysis of mutation in the human FBN1 gene. // Nucleic. Acids. Res. 1997. — Vol.25. — P. 147−150.
- Collod-Beroud G., Boileau C. Marfan syndrome in third Millennium. // Eur. J. Hum. Genet. 2002. — Vol.10. — P. 673−681.
- Collod-Beroud G., Bourdelles S., Ades L., et al. Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database // Hum. Mutat. 2003. — Vol.22 — P.199−208.
- Corson G, Chalberg S, Dietz H, Charbonneau N, Sakai L. Fibrillin binds calcium and is coded by cDNAs that reveal a multidomain structure and alternatively spliced exons at the 5' end // Genomics. 1993. — Vol.17 — P. 476 — 484.
- Cotton R.G.H. Mutation detection and mutation database //Clin. Chem. Lab. Med. 1998. — Vol.36(8) — P.519−522.
- De Bie S., De Paepe., Delvaux I., Davies S., Hennekam R. Marfan syndrome in Europe // Com. Genet. 2004. — Vol.7 — P. 216−225.
- De Paepe A., Devereux R., Dietz H. et al. Revised diagnostic criteria for the Marfan syndrome. // Am. J. Med. Genet. 1996. — Vol.62. — P. 417−426.
- Dean J. Management of Marfan syndrome. // Heart. 2002. Vol.88. — P. 97−103.
- Dietz H. C., Pyeritz R. E., Puffenberg E. G. et al. Marfan phenotype variability in a family segregating a missense mutation in the epidermal growth factor-like motif of fibrillin gene. // Clin. Genet. 1992. — Vol.89. — P. 1674−1670.
- Dietz H., Cutting G., Pyeritz R. et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. // Nature-1991. Vol.352. — P. 337−339.
- Edwards M., Challinor CJ., Coley P. W. et al. Clinical and linkage study of a large family with simple ectopia lentis linked to FBN1 // Am. J. Med. Genet. -1994.- Vol.53 -P.573−576.
- Fleisher K., Nousari H., Anhalt G., Stone C., Laschinger J. Immohistochemical abnormalities of fibrillin in cardiovascular tissues in Marfan’s syndrome // Ann. Thorac. Surg. 1997. — Vol.63 — P. 1012−17.
- Francke U., Berg M., Tynan K. et al. A Gly 1127Ser mutation in an EGF-like domain of the fibrillin-1 gene is a risk factor for ascending aortic aneurysm and dissection. // Am. J. Hum. Genet. 1995. — Vol.56. — P. 1287−1296.
- Geva Т., Sanders S. P., Diogenes M.S., Rockenmacher S., Van Praagh R. Two-dimensional and doppler echocardiographic and pathologic characteristics of the infantile Marfan syndrome // Am. J. Cardiol. 1990. — V.65. -P.l230−1237.
- Giltay R., Kostka G., Timpl R. Sequence and expression of a novel member (LTBP-4) of the family of novel latent transforming growth factor- (3 protein // FEBS Lett 1997. — Vol.411 — P. l64−168.
- Glanville RW, Qian RQ, McClure DW, Maslen CL. Calcium binding, hydroxylation, and glycosylation of the precursor epidermal growth factor-like domains of fibrillin-1, the Marfan gene protein // J. Biol. Chem. 1994. — Vol. 269.-P. 26 630−26 634.
- Godfrey M., Raghunath M., Cisler J. et al. Abnormal morphology of fibrillin microfibrils in fibroblast cultures from patients with neonatal Marfan syndrome. // Am. J. Hum. Genet. 1995. — Vol.146. — P. 1414−1421.
- Gray J.R., Bridges A.B., Faed M.J., Pringle Т., Baines P., Dean J., Boxer M. Ascertainment and severity of Marfan syndrome in a Scottish population // J. Med. Genet.-1994.- V.31 P.51.54.
- Greally M., Carey J., Milewicz D. et al. Shprintzen-Goldberg syndrome: a clinical analysis. // Am. J. Med. Genet. 1998. — Vol. 76. — P. 202−212.
- Grompe M. The rapid detection of unknown mutations in nucleic acids // Nature Genet.- 1993.-Vol.5-P. 111−117.
- Guisti В., Porciani M.C., Brunelli T. et al. Phenotypic variability of cardiovascular manifestations in Marfan syndrome: possible role of hyperhomocysteinemia and C677T MTHFR gene polymorphism // Eur. Heart. J. 2003. — Vol.24 — P.2038−2045.
- Hanford P. A, Mayhew M., Baron M., Winship P.R., Campbell I.D., Brownlee G.G. Key residues involved in calcium-binding motifs in EGF-like domains // Nature. 1991- Vol.351. P -164−167.
- Hayward C., Porteous M.E., Brock D.J. A novel mutation in the fibrillin-1 gene (FBNI) in familial arachnodactyly // Mol. Cell. Probes 1994. — Vol.8. P.325−327.
- Hollister D., Godfrey M., Sakai., Pyeritz R. Immunohistologic abnormalities of the microfibrillar-flber system in the Marfan syndrome. // N. Eng. J. Med. — 1990.-Vol.323.-P. 152−159.
- Hynes R. Integrins: versality, modulation, and signaling in cell adhesion. // Cell. 1992.-Vol.69.-P. 11−25.
- Jensen S. A., Reinhardt D. P., Gibson M.A., Weiss A.S. Protein interaction studies of MAGP-1 with tropoelastin and fibrillin-1 // J. Biol. Chem. 2001.-Vol.276. — P.39 661−39 666.
- Judge D., Biery N., Dietz H. Characterization of microsatellite markers flanking FBNI: Utility in the diagnostic evalution for marfan syndrome // Am. J. Med.Genet. 2001.- Vol.99 — P.39−47.
- Kainulainen K., Karttunen L., Puhakka L. et al. Mutations in the fibrillin gene responsible for dominant ectopia lentis and neonatal Marfan syndrome. // Nature Genetics. 1994.-Vol.6. — P. 64−69.
- Kainulainen K., Pulkkinen L., Savolainen A., Kaitila I., Peltonen L. Location on chromosome 15 of the gene defect causing Marfan syndrome. // N. Engl. J. Med. 1990. — Vol.323. — P. 935−939.
- Kainulainen K., Sakai L.Y., Child A. et al. Two mutations in Marfan syndrome resulting in truncated fibrillin polypeptides. Proc. Natl. Acad. Sci. USA 1992.-Vol.89. -P. 5917−5921.
- Katzke S., Booms P., Tiecke F., Palz M. et al. 'TTGE screening of the entire FBN1 coding sequence in 126 individuals with Marfan syndrome and related fibrilinopathies // Hum. Mutat. 2002.-Vol.20. — P. 197−208.
- Keene D.R., Maddox B.K., Kuo H.J., Sakai L.Y., Glanville R.W. Extraction from extendable structures and their identification as fibrillin-containing extracellular matrix microfibrillis // J. Histochem. Cytochem. 1991. — Vol.39 -P.441−449.
- Kettle S., Yaun X., Grundy G., Knott V., Downing A.K., Hanford P.A.
- Defective calcium binding to fibrillin-1: consequence of an N2144S change for fibrillin-1 structure and function // J. Mol. Biol. 1999. — Vol.285. — P-1277−1287
- Knott V., Downing A.K., Cardy C.M., Hanford P. Calcium binding properties of an epidermal growth factor-like domain pair from human fibrillin-1 // J. Mol. Biol. Vol.255. — P. 22−27.
- Krawczak M., Konecki D.S., Schmidtke I. et al. Allelic association of the cystic fibrosis locus and two DNA markers, Xv-2c and KM-19 in 55 German families //Hum. Genet.- 1988.- V. 80.- № i. p. 78−80.
- Lee В., Godfrey M., Vitaele E. et al. Linkage of Marfan syndrome and phenotypically related disorder to two different fibrillin genes. // Nature. 1991. -Vol.352.-P. 330−334.
- Lee B.N. Cheong H. I., Shin et al. The effect of C677T mutation of methylenetetrahydro folate reductase gene and plasma folate level on hyperhomocysteinemia in patients with meningomyelocele // Child’s Nerv. Syst. 2000. — Vol.16. — P. 559−563.
- Lipscomb K. J., Clayton-Smith J., Harris R. Evolving phenotype of Marfan’s syndrome //Arch. Dis. Child. 1997.- Vol.76. — P. 41- 46.
- Liu W., Schrijver I., Brenn Т., Francke U. Multi-exon deletions of the FBN1 gene in Marfan syndrome // BMC. Med. Genet. 2001. — Vol.2. — P. 11−19.
- Loeys B, De Backer J, Van Acker P, et al. Comprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome // Hum. Mutat. 2004. — V.24. — P. 140—146.
- Loeys В., Nuytinck L., Delvaux I, et al. Genotype and phenotype analisis at 171 patients referred for molecular study of the fibrillin-1 gene because of suspected Marfan syndrome // Arch. Intern. Med. 2001. — Vol.161. — P.2447−54.
- Lonqvist L., Child A., Kainulainen K., Davidson R., Puhakka L., Peltonen L. A novel mutation of the fibrillin gene causing ectopia lentis. // Genomics. 1994. Vol.19.-P. 573−576.
- MacArthur M.W., Thornton J.M. //J. Mol. Biol. -1991. Vol.218. — P. 397−412.
- Maddox, B.K., Sakai, L.Y., Keene, D.R., Glanville, R.W. Connective tissue microfibrils. Isolation and characterization of three large pepsin-resistant domains of fibrillin//J. Biol. Chem. 1989. — V.264. -P. 21 381−21 385.
- Magenis R.E., Maslen C.I., Smith I., Allen I., Sakai Y. Localization of the fibrillin (FBN) gene on chromosome-15 band q21.1//Genomics. -1991. Vol.11.-P.346−351.
- Majors A.K., Pyeritz R.E. A deficiency of cysteine impairs fibrillin-deposition: implication for pathogenesis of cystathionine betasynthase deficiency //Mol. Genet. Metab. 2000. — Vol.70 — P. 252−260.
- Marfan A: Un cas de de’formation conge’nitale des quatre membres, plus prononce’e aux extre’mite’s, caracte’rise’e par l’allongement des os avec un certain degre' d’amincissement // Bull Me’m Soc Me’d Ho"p 1896. — Vol. 13.--P. 220−227.
- McGettrick A., Knott V., Willis, A., Hanford P. Molecular effects of calcium binding mutations in Marfan syndrome depend on domain context // Hum. Mol. Genet. 2000. — Vol.9. — P. 1987−1994.
- McKuisck V. The cardiovascular aspects of Marfan Syndrome: A heritable disorder of connective tissue. // Circulation. 1955. — Vol.11. — P. 321−341.
- McKusick V. The defect in Marfan syndrome.//Nature.- 1991. Vol.352.- P. 279−281.
- Mathew C.C. The isolation of high molecular weight eucariotic DNA // Methods in molecular biology / Ed. Walker J.M. N.Y.- Haman press, 1984.- P.31−34.
- Milewicz D., Grossfield J., Cao S.N., Kietly C., Covitz W., Jewett T. A mutation in FBN1 disrupts profibrillin pressing and results in isolated skeletal features of the Marfan syndrome // J. Clin. Invest. 1995. — Vol.95. — P. 2373−2378.
- Milewicz D., Michael K., Fisher N., Coselli J., Markello Т., Biddinger A. Fibrillin-1 (FBN1) mutations in patients with thoracic aortic aneurysms // Circulation. 1996. — Vol.94 — P. 2708−2711.
- Miyao M., Morita H., Hosoi T et al. Methylentetrahydrofolate reductase polymorphism and bone mineral density in postmenopausal Japanese women // J. Bone Min. Res. 1998. — Vol. l3S373 -P.304.
- Mizuguchi Т., Collod-Beroud G., Akiyma Т., Abifadel M., NaradaN., Morisaki Т., Allard D. Heterozygous TGFBR2 mutations in Marfan syndrome 2004. -Vol.36-P.855−860.
- Moren A., Olofsson A., Stennman G et al. Identification and characterization of LTBP-2, a novel latent transforming growth factor- (3 protein // J. Biol. Chem. -1994. Vol.269 — P.32 469−78.
- Nagashima H., Sokomura Y., Aoka Y., et al. Angeotensin II type 2 receptor mediates muscle cell apoptosis in cystic medical degeneration associated with Marfan’s syndrome // Circulation 2001. — Vol.104 (suppll): 1−228−7.
- Nei M. Molecular Population Genetic and Evolution. Amsterdam: North-Holland, 1975.-P.278.
- Neptune E.R., Frishcmeyer P.A., Arkung D.E., Mayers et al. Dysregulation of TGF- P activation to pathogenesis in Marfan Syndrome // Nat. Genet. 2003. -Vol.33. -P. 407−411.
- Palz M., Tiecke F., Booms P., Goldner В et al. Clustering of mutations associated with mild Marfan-like phenotypes in the 3' region ofFBNl suggests sy<) potential genotype-phenotype correlation. 2000. — Vol.91 — P.212- 221.
- Pereira L., Andrikopoulos K., Tian J. et al. Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome // Nat. Genet. -1997.-Vol.17-P.218−22.
- Pereira L., D’Alessio M., Ramirez F et al. Genomic organization of the sequence coding for fibrillin, the defective gene product in Marfan syndrome // Hum. Mol. Gen. 1993. — Vpl.2 — P.1762.
- Pereira L., Levran O., Ramirez F., Lynch J.R., Sykes В., Pyeritz R.E., Dietz H.C. A molecular approach to the strati. cation of cardiovascular risk in families with Marfaris syndrome // N. Engl. J. Med. 1994. — Vol.331 — P.148−153.
- Pfaff M., Reinhardt D.P., Sakai L.Y., Timpl R. Cell adhesion and integrin binding to recombinant human fibrillin-1 // FEBS Leu 1996.- Vol.384. — P-245−250.
- Powell Т., Turner R., Henney A., Miller G. An association between arterial pulse pressure and variation in the fibrillin-1 gene. // Heart. 1997. — Vol.78. -P. 396−398.
- Pyeritz R. E. The Marfan syndrome. New York: Wiley-Liss, 1993. — P. 437 468.
- Pyeritz R. E. The Marfan syndrome.// Annu. Rev. Med 2000. — Vol.51 — P. 481−510.
- Pyeritz R.E., McKusick V.A. The Marfan syndrome: diagnosis and management // N. Engl. J. Med. 1979. — Vol.300. — P. 772−777.
- Quondamatteo F., Reinhardt D., Charbonneau N., Pophal G., Sakai L., Herken R. Fibrillin-1 and fibrillin-2 in human embiyonicand early fetal development // Matr. Biol. 2002. — V. 21. — P.637−646.
- Raghunanth M., Kietly C., Stiemann B. Truncated profibrillin of a Marfan patient leads to over-N-glycosilation. // J. Mol. Biol. 1995. — Vol.248. — P. 901−909.
- Ramirez F. The fibrillins./Ant. J. Biochem. Cell Biol.-l999.Vol.31.-P. 255−259.
- Rantamaki T, Lonnqvist L, Karttunen L, Kainulainen K, Peltonen L. DNA diagnostics of the Marfan syndrome: application of applifable polymorphic markers // Eur. J. Hum. Genet. 1994. — Vol.2 — P.66−75.
- Rantamaki Т., Karttunen L., Peltonen L. Badly engineered fibrillin: lessons from molecular studies of marfan syndrome // Trends. Cardiovasc. Med. -1997.- Vol.7-P282−288.
- Reinhardt D., Keene D. R., Corson G.M. et al. Fibrillin-1 organization in microfibrillis and structural properties // J. Mol. Biol. 1996. — Vol.258 — P. 104 116.
- Reinhardt D., Ono R., Sakai L. Calcium stabilizes fibrillin-1 against proteolytic degradation. // J. Biol. Chem. 1997. Vol. 272. — P. 1231−1236.
- Reinhardt D.P., Sasaki Т., Dzamba D. et al. Fibrillin-1 and fibullin-2 interact and colocalized in some tissues // J. Biol. Chem. 1996. — Vol.271 — P. l9489−96.
- Richmond J., Hui H., Hwa J., McCarron H., Clifford F., Richards J. Relation between age, arterial distensibility and aortic dilatation in the Marfan Syndrome // Am. J. Card. 1994. — V.74. — P.369−373.
- Robinson P., Godfrey M. The molecular genetics of Marfan syndrome and related microfibrillopathies. // J. Med. Genet. 2000. — Vol.37. — P. 9−25.
- Roff D.A., Bentzen P. The statistical analysis of mitochondrial DNA: % and problem of small samples // Mol. Biol. Evol.- 1989.- V. 6.- P. 539−545.
- Roman MJ, Rosen SE, Kramer-Fox R, Devereux RB. The prognostic significance of the pattern of aortic root dilatation in the Marfan syndrome // J. Am. Coll. Cardiol. 1993. — V.22. — P.1470 -1476.ч
- Rosen R. Genetic modulation of homocysteinemia // Semin Thromb Hemost -2000. Vol.22-P. 255−261.
- Rupp P., Maslen C. Interaction of the fibrillins with laminin 02 identified by yeast two hybrid analisis (abstract) // Eur. J. Pediatr. 1996. — Vol. l55 — P. 736.
- Sakai L., Keene D., Engvall E. Fibrillin, a new 350-kD glycoprotein, is a component of extracellular microfibrils. // J. Cell. Biol. — 1986. Vol.103. — P. 2499−2509.
- Sakamoto H., Broekelmann Т., Cheresh D., Ramirez F. etal. Cell-type cpecific recognition of RGD- and non-RGD-containing cell binding domains in fibrillin-1. // J. Biol. Chem. 1996. — Vol.271. — P. 4916−4922.
- Seshadri S., Beiser A., Selhub J et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease //N. Engl. J. Med 2002.-Vol.346.- P.476−83.
- Sham P.C., Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci//Ann. Hum. Genet.-1995.-Vol.59.-P. 97−105.
- Shores J., Berger K., Murphy E., Pyeritz R. Progression of aortic dilatation and the benefit of long-term {3-andrenergic blockade in Marfan’s syndrome. // N. Engl. J. Med. 1994. — Vol.330. — P. 1335−1341.
- Shrijver I., Liu W., Francke U. The pathogenicity of the Pro 1148Ala substitution in the FBN1 gene: causing or predisposing to Marfan syndrome and aortic aneurysm, or clinically innocent?//Hum.Genet.- 1997.-Vol.99 P.601−611.
- Silverman DI, Burton KJ, Gray J et al. Life expectancy in the Marfan syndrome // Am. J. Cardiol. -1995. Vol. 75 — P. 157−60.
- Sood S., Eldadah Z. et al. Mutation in fibrillin-1 and the Marfanoid-craniosynostosis (Shprintzen-Coldberg) syndrome. // Nat. Genet. 1996.-Vol.l2.-P.209−211.
- Terada Т., Yokoto H., Tsuura M., Nakai R., Ohshima A., Itakura T. Marfan syndrome associated with moyamoya phenomenon and aortic dissection. // Acta Neurochir.-1999. Vol.141. — P. 663−665.
- The FBN1 mutations database. http://www.umd.be:2030/
- Tiecke F., Katzke S., Booms P., Robinson P., Godfrey M. et al. Classic, atypically severe and neonatal Marfan syndrome: twelve mutations and genotype-phenotype correlations in FBN1 exons 24−40. // Eur. J. Hum. Genet. -2001.-Vol.9-P. 13−21.
- Tsipouras P. et al. Marfan syndrome is closely linked to a marker on chromosome 15ql.5—>q2.1. // Proc. Natl. Acad. Sci. USA. 1991. — Vol.88. -P.4486−4488.
- Ueland P. M., Hustad S., Schneede J et al. Biological and clinical implicationsof the MTHFR C677T polymorphism // Trends in Pharmacol Sci 2001.-Vol.22. -P. 195−201.
- Vaughan CJ, Casey M, He J et al. Identification of a chromosome Iq23.2-q24 locus for familial aortic aneurysm disease, a genetically heterogeneous disorder // Circulation. 2001. — V.103. — P. 2469−75.
- Wang M., Clericuzio C.L., Godfrey M. Familial occurrence of typical and severe lethal congenital contractural arachnodactyly caused by missplicing of 34 exon of fibrillin-2 // Am. J. Hum. Genet. 1996. — Vol.59 — P. 1027−1034.
- Wang M., Kishnani P., Decker-Phillips M., Kahler S., Godfrey M. Doublek>mutant fibrillin-1 (FBN1) allele in a patient with neonatal Marfan syndrome. // J. Med. Genet. 1996. — Vol.33. — P. 760−763.
- Weve H. U" ber Arachnodaktylie (dystrophia mesodermalis congenita, Typus Marfan) // Archiv. Augenheilk 1931. — Vol. 104. P. — 46.
- Wheatley H.M., Traboulsi E.L., Flowers B. E at al. Immunohistochemical localization of fibrillin in human ocular tissue // Connect. Tissue. Res. — 1995. -Vol.113-P.103−109.
- Whiteman P., Downing K., Hanford P. NMR analysis of cbEGF domains gives new insights into the structural consequences of a P1148A substitution infibrillin 1 // Protein. Eng. 1998. — Vol. 11 — P. 957−959.
- Writz M., Samples J., Kramer P. et al. Weil-Marchesani syndrome possible linkage of the autosomal dominant form to 15. q21.1. // Am. J. Med. Genet. -1996.-Vol.65.-P.68−75.
- Wu-Chen W.Y., Letson R.D., Summers C.G. Functional and structural outcomes following lensectomy for ectopia lentis // J. AAPOS. 2005. — V.4 -P. 353−357.
- Yaun X., Downing A.K., Knott V., Hanford P.A. Solution structure of the transforming growth factor b-binding protein like module, a domain associated with matrix fibrillis // EMBO J. 1997. — Vol.15. — P- 6659−66.
- Yin W., Smiley E., Germiller J. et al. Isolation of a novel latent transforming growth factor- p protein //J. Biol. Chem. 1995. — Vol.270. — P. 1798−806
- Zhang H., Apfelroth S., Hu W. et al. Structure and expression of fibrillin-2, a novel microfibrillar component preferentially located in elastic matrices. // J. Cell. Biol. 1994. — Vol.124. — P. 885−863.
- Zhang H., Hu W., Ramirez F. Developmental expression of fibrillin genes suggests heterogeneity of extracellular microfibrills // J. Cell. Biol-1995. -Vol.129- P. 1165−76.